Cardiac hypertrophy: Targeting Raf/MEK/ERK1/2-signaling

被引:106
|
作者
Lorenz, Kristina [1 ]
Schmitt, Joachim P. [1 ]
Vidal, Marie [1 ]
Lohse, Martin J. [1 ,2 ]
机构
[1] Univ Wurzburg, Inst Pharmacol & Toxicol, D-97078 Wurzburg, Germany
[2] Univ Wurzburg, Rudolf Virchow Ctr, DFG Res Ctr Expt Biomed, D-97078 Wurzburg, Germany
关键词
Cardiac hypertrophy; ERK1/2; Signaling; ACTIVATED PROTEIN-KINASE; EXTRACELLULAR SIGNAL; DIFFERENTIAL REGULATION; DILATED CARDIOMYOPATHY; INDUCED APOPTOSIS; HEART; INHIBITION; PATHWAY; DYSFUNCTION; MECHANISMS;
D O I
10.1016/j.biocel.2009.08.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Over the past two decades, basic research has revealed a complex network of regulatory mechanisms that control the ERK1/2-signaling cascade. ERK1/2 mediate cardiac hypertrophy, a major risk factor for the development of arrhythmias, heart failure and sudden death, but also beneficial effects, e.g. protection of the heart from cell death and ischemic injury. Selective targeting of these ambiguous ERK functions could provide a powerful tool in the treatment of cardiac disease. This short review will discuss new mechanistic insights into ERK1/2-dependent development of cardiac hypertrophy and the prospect to translate this knowledge into future therapeutic strategies. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2351 / 2355
页数:5
相关论文
共 50 条
  • [1] Noncatalytic Function of ERK1/2 Can Promote Raf/MEK/ERK-mediated Growth Arrest Signaling
    Hong, Seung-Keun
    Yoon, Seunghee
    Moelling, Cas
    Arthan, Dumrongkiet
    Park, Jong-In
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (48) : 33006 - 33018
  • [2] Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma
    Wang, Ao-Xue
    Qi, Xiao-Yi
    IUBMB LIFE, 2013, 65 (09) : 748 - 758
  • [3] The dimer interface of ERK1/2 provides an alternative targeting strategy to interfere with ERK1/2 mediated cardiac hypertrophy
    Tomasovic, A.
    Huemmert, M.
    Kramer, S.
    Gruse, T.
    Katus, H. A.
    Lohse, M. J.
    Mueller, O.
    Lorenz, K.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2016, 389 (01) : S4 - S5
  • [4] Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
    Degirmenci, Ufuk
    Wang, Mei
    Hu, Jiancheng
    CELLS, 2020, 9 (01)
  • [5] Selective interference with nuclear ERK1/2 signaling prevents pathological cardiac hypertrophy
    Ruppert, C.
    Vidal, M.
    Lohse, M. J.
    Lorenz, K.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 : S68 - S68
  • [6] SPECIFIC INTERFERENCE WITH NUCLEAR ERK1/2 SIGNALING PREVENTS PATHOLOGICAL CARDIAC HYPERTROPHY
    Ruppert, C.
    Deiss, K.
    Herrmann, S.
    Vidal, M.
    Oezkur, M.
    Gorski, A.
    Weidemann, F.
    Lohse, M. J.
    Lorenz, K.
    CARDIOLOGY, 2013, 126 : 17 - 17
  • [7] Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy
    Kehat, Izhak
    Molkentin, Jeffery D.
    ANALYSIS OF CARDIAC DEVELOPMENT: FROM EMBRYO TO OLD AGE, 2010, 1188 : 96 - 102
  • [8] ERK1/2-signaling is required for cell differentiation during ocular lens development
    Reneker, Lixing W.
    DEVELOPMENTAL BIOLOGY, 2009, 331 (02) : 484 - 485
  • [9] A new potential strategy for targeting pathological cardiac hypertrophy: the dimer interface of ERK1/2
    Tomasovic, A.
    Huemmert, M.
    Lorenz, K. Kristina
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 432 - 432
  • [10] CREG, a new regulator of ERK1/2 in cardiac hypertrophy
    Xu, L
    Liu, JM
    Chen, LY
    JOURNAL OF HYPERTENSION, 2004, 22 (08) : 1579 - 1587